长药控股投资者索赔再提交法院立案，前期已有胜诉判决

Core Viewpoint - Long Pharmaceutical Holdings (300391) is facing legal actions due to allegations of false financial reporting, with investors seeking compensation through lawsuits [1][2] Group 1: Legal Proceedings - Long Pharmaceutical Holdings has submitted multiple claims to the Wuhan Intermediate People's Court regarding investor compensation for false statements, with previous successful cases as a precedent [1] - The law firm representing the investors is actively accepting new claims and is awaiting further court arrangements [1] Group 2: Regulatory Actions - On November 7, 2025, Long Pharmaceutical Holdings received a notice from the China Securities Regulatory Commission (CSRC) regarding an investigation into the company for suspected false financial reporting [1] - The company issued a risk warning on April 30, 2024, indicating issues related to fund occupation and potential risks to its stock due to audit concerns [1] Group 3: Financial Issues - Long Pharmaceutical Holdings reported a significant fund occupation of approximately 179.66 million yuan, which constitutes 92.08% of the company's latest audited net assets [2] - The company plans to resolve the fund occupation through the transfer of debts with related parties [2] Group 4: Investor Compensation - Investors who purchased Long Pharmaceutical Holdings stock between March 30, 2019, and April 30, 2024, and sold or held the stock after April 30, 2024, may still initiate compensation claims [2]